Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.57 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95814 | 0.85 | SLC18A3 (0.69) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL3458641 | 0.82 | SIGMAR1 (0.69) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL8575657 | 0.81 | DRD2 (0.50) | SLC18A3DRD2SIGMAR1DRD3 | |
| SCHEMBL2097765 | 0.80 | SIGMAR1 (0.69) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL1003503 | 0.80 | DRD2 (0.73) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL11684911 | 0.80 | SLC18A3 (0.62) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL8967407 | 0.80 | SLC18A3 (0.73) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL175904 | 0.79 | SLC18A3 (0.57) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL9434095 | 0.79 | SIGMAR1 (0.70) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL9557866 | 0.79 | CYP11B2 (0.57) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6048877-A | Tetralone derivatives as antiarrhythmic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-04-11 | — | — | US | claimed |
| US-5276150-A | Vasodilators, anticoagulants, calcium channel blockers | FUJIREBIO INC. (JP) | 1994-01-04 | — | — | US | claimed |
| EP-0400660-A1 | 1,4-dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1990-12-05 | — | — | EP | claimed |
| US-4104380-A | Dibenzyl glycolic acid derivatives | WARNER-LAMBERT COMPANY (US) | 1978-08-01 | — | — | US | claimed |
| US-4076937-A | Dibenzyl glycolic acid derivatives | WARNER-LAMBERT COMPANY (US) | 1978-02-28 | — | — | US | claimed |
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | disclosed |
| US-7482372-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2005-08-04 | — | — | US | disclosed |
| US-6906053-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-6890915-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2004-10-21 | — | — | US | disclosed |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | disclosed |
| WO-2002096426-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-1998008839-A1 | COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED THIOPHENE LIBRARIES | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| US-5688820-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ADIR ET COMPAGNIE (FR) | 1997-11-18 | — | — | US | disclosed |
| EP-0487408-B1 | Oxazolopyridine derivatives, process for their preparation and pharmaceutical compositions comprising the same | ADIR (FR) | 1995-06-21 | — | — | EP | disclosed |
| US-5276150-A | Vasodilators, anticoagulants, calcium channel blockers | FUJIREBIO INC. (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0487408-A1 | Oxazolopyridine derivatives, process for their preparation and pharmaceutical compositions comprising the same | ADIR ET COMPAGNIE (FR) | 1992-05-27 | — | — | EP | disclosed |
| EP-0400660-A1 | 1,4-dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | SLC18A3 2842/4885DRD2 4073/4885SIGMAR1 3783/4885 |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM9 | SLC18A3 2461/4885DRD2 4123/4885SIGMAR1 3232/4885 |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | PLK4, PDXK, PLK2 | SLC18A3 4810/4885DRD2 4618/4885SIGMAR1 3314/4885 |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | SLC18A3 2842/4885DRD2 4073/4885SIGMAR1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.